ARENA PHARMACEUTICALS is in a rapidly changing global market, where we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to discover and develop medicines for patients, and relentlessly execute until it’s done.

Our GI research portfolio includes etrasimod, a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, currently in Phase 3 for ulcerative colitis, in a Phase2/3 seamless program for Crohn’s disease, and in Phase 2 for eosinophilic esophagitis.

Etrasimod is an investigational compound, not approved for use in any country.

Resources

Arena Corporate Video

IBD MOD Video

GLADIATOR Booth Brochure

CULTIVATE Booth Brochure

For more information, please contact: